ALLO Stock Forecast & Price Target

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T cell therapies with a strong pipeline and multiple partnerships. Despite a recent stock price decline, the company's promising interim futility results and potential for positive survival outcomes in LBCL make it an attractive buy for investors. Additionally, the recent stock offering provides an opportunity for financial growth.

Allogene Therapeutics is facing significant challenges with its clinical stage immuno-oncology products in the current market, with only a 41.6% delta surpassing the management's 25-30% bar for clinical meaningfulness with no G3+ CRS, ICANS, GVHD, or infection reported. The data also showed that ~33% of screening activity and cema-cel infusions were conducted in community cancer centers, which may indicate a decreased interest in the study. The company's goal of activating 80 sites by year-end already occurred in July, but the enrollment of 220 patients will take until YE2027, resulting in a delayed interim EFS analysis in mid-2027 and a primary EFS analysis by mid-2028.